ResearchResearch summary
Oral and topical treatments for uncomplicated vaginal yeast infection
A 50-trial network meta-analysis found high efficacy across active treatments and did not support a strict route hierarchy.
In this pathway
- Current topic
- Oral and topical treatments for uncomplicated vaginal yeast infectionCurrent
Bottom line
Both oral and topical treatments had high cure proportions; selected outcomes modestly favored oral fluconazole, but the review did not support a strict hierarchy.
Why this source matters
It is the current large synthesis comparing early and late symptom and mycological outcomes across acute uncomplicated-VVC regimens.
Study and population
The network included 50 randomized studies and 7,208 participants treated for uncomplicated VVC.
What was tested
The review compared single- and multiple-day oral and topical treatments for clinical and mycological cure at 7–10 and 24–35 days.
Results
Every studied active treatment exceeded 75 cures per 100 participants. Oral fluconazole was modestly favored for early clinical and late mycological cure, while late clinical cure did not differ significantly by route.
Applicability
The estimates apply to studied uncomplicated-VVC populations, not recurrent or higher-risk populations and not individual route selection.
Limitations
Regimens and trials varied, network comparisons include indirect evidence, and important higher-risk populations were largely excluded.
Contribution to the evidence
Supporting. The review updates acute-treatment comparisons while explicitly preserving the no-strict-hierarchy boundary.
Practical change
No practical change. The result does not rank one route for every person.
Funding and conflicts
The indexed record reported no funding source and the authors reported no conflict of interest.
Source
Read the original publication (published 27 March 2025).
Study type, population, and sample scale
- Study type
- Systematic review and Bayesian network meta-analysis of randomized trials
- Population
- Participants in randomized studies of active oral or topical treatment, with or without placebo, for uncomplicated vulvovaginal candidiasis
- Sample scale
- 50 randomized studies with 7,208 participants
Results
- Across the 7,208 participants, each studied active treatment achieved clinical and mycological cure in more than 75 per 100 participants compared with placebo.
- Single-dose oral fluconazole had higher odds of early clinical cure than multiple-day topical treatment (network odds ratio 1.52, 95% CI 1.13 to 2.07), but among 3,983 participants in the late-clinical-cure network there was no significant oral-versus-topical difference.
- Single-dose fluconazole was marginally favored for late mycological cure (odds ratio 1.42, 95% CI 1.00 to 1.99); the authors said high efficacy across routes made a strict hierarchy inappropriate.
Limitations
- Active regimens had high cure proportions and some early or mycological outcomes favored oral fluconazole.
- Network estimates combine heterogeneous regimens and trials and do not establish one best treatment for an individual.
- Late clinical cure did not differ significantly by oral or topical route.
- The included uncomplicated populations largely excluded pregnancy, breastfeeding, immunocompromise, and diabetes.
Applies to
- Group-level comparison of studied oral and topical regimens for uncomplicated VVC
Does not apply to
- Pregnancy, breastfeeding, immunocompromise, diabetes, complicated or recurrent VVC, or an individualized treatment ranking
Contribution to the current conclusion
Supporting
This current synthesis of 50 randomized studies materially updates the acute-treatment comparison while explicitly warning against a strict treatment hierarchy; a summary can separate symptom and mycologic outcomes and preserve population exclusions.
Related evidence mapPractical change or no change
No practical change. The review updates comparative estimates but supports keeping route choice separate from a strict efficacy ranking.
Funding and conflicts
- Funding
- No funding source was reported in the indexed record.
- Conflicts
- The authors reported no conflict of interest.
- Paper date
- 2025-03-27
Sources
View all 1 source
- Treatment of uncomplicated vulvovaginal candidiasis: topical or oral drugs? Single-day or multiple-day therapy? A network meta-analysis of randomized trials
- Source type
- Systematic review
- Published
- 2025-03-27